$MIST

Milestone Pharmaceuticals (MIST) announced the first Canadian patient enrollment in the ReVeRA-301 Phase 3 trial for etripamil nasal spray, targeting atrial fibrillation with rapid ventricular rate (AFib-RVR). The study aims to enroll 150 patients globally, evaluating the 70 mg dose already FDA-approved for PSVT as CARDAMYST.

French AI startup Mistral raised €3B, valuing it at €21B. Milestone Pharmaceuticals (MIST), a biotech firm, has a high P/S ratio of 57.14, weak financials, and insider selling. Investors should exercise caution due to growth assumptions and financial distress signals.

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

Milestone Pharmaceuticals (MIST) announced China's approval of etripamil nasal spray for treating PSVT in adults, triggering a $2M milestone payment. Everest Medicines holds exclusive rights in Greater China, with up to $98M in potential milestones and 18% royalties. The approval was based on Phase 3 study data showing significant efficacy over placebo.

Milestone Pharmaceuticals (MIST) began a Phase 3 trial for etripamil nasal spray to treat AFib-RVR. The study aims to assess rapid ventricular rate reduction and symptom improvement in unsupervised settings. MIST seeks FDA approval based on existing safety data. The stock traded between $1.00 and $3.06 in the past year, closing at $1.03 on Thursday.

Milestone Pharmaceuticals (MIST) shares rose 3.9% after enrolling the first patient in its Phase 3 ReVeRA-301 trial for etripamil in treating AFib-RVR. The trial evaluates the same 70 mg dose approved for PSVT. The study aims to enroll 150 patients, with primary and secondary endpoints focused on ventricular rate reduction and symptom improvement. Milestone seeks FDA approval for home use. AFib affects 6 million U.S. patients, with projected economic costs rising to $174.8 billion by 2050, accor

Milestone Pharmaceuticals (MIST) reported Q2 2026 earnings, with product revenue of $559,000 and a net loss of $28.6 million. The company saw a fourfold increase in prescriptions and 50% commercial insurance coverage for CARDAMYST. Management expects cash runway into 2H 2027 and anticipates Medicare coverage in 2027. The Phase III trial for AFib-RVR is underway, targeting a larger patient population.

Milestone Pharmaceuticals (NASDAQ:MIST) reported Q2 product revenue of $0.6M versus none a year earlier, and a net loss of $28.6M ($0.21/share). Management said CARDAMYST prescriber uptake and payer coverage improved, with coverage at about 25% of commercially insured lives and plans to expand. Milestone also started registrational enrollment for ReVeRA-301 etripamil in AFib-RVR.

Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.

Milestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil) nasal spray Phase